The central focus of Pharmorage is the development of oligonucleotide technologies that modulate inflammation at its source.
In collaboration with Hudson Institute of Medical Research, Pharmorage is investigating ultra-short 3-base oligonucleotides (known as 3-mers) with the intention of reducing mRNA vaccine side effects through inhibiting TLR7 (Toll-like receptor 7). Pharmorage’s SOF-VAC asset is intended to enhance mRNA COVID vaccines, as well as future mRNA vaccines and therapeutics.
Pharmorage is a fully owned subsidiary of Noxopharm Limited. More information on the science and latest research can be found on the Noxopharm website.